Harbor
Spring 2026 NewAI system-of-record for clinical trial data
Harbor is a new, AI-enabled system of record for clinical trial data that replaces legacy electronic data capture (EDC) systems. Today, medical device and pharma companies spend months setting up custom EDCs that research sites then spend hours per subject per day entering data into. With Harbor, the EDC is spun up simply by reading your clinical trial protocol and research sites upload raw source documents into the platform, skipping the tedious and error-prone data entry process altogether. EDCs haven’t fundamentally changed since the 1990s. They are passive, regulatory compliant data bins that cause massive trial delays, coordinator burnout, and weeks of back-and-forth to resolve data errors. Because of this, data management currently consumes ~30% of total clinical trial budgets. With LLM and document extraction capabilities finally reaching the accuracy, reliability, and traceability required in high-risk domains, Harbor is redefining the way data is collected and monitored in clinical trials, all while remaining fully GCP- and 21 CFR Part 11 compliant. After months of building our initial product, our platform is now live with its first few clinical studies. For our largest customer and their 1600 subject randomized trial, we were able to use our internal tools to get their study database configured in just one week, which was ten times faster than legacy EDC vendors quoted. We built Harbor because we lived through this problem. Albert spent four years in clinical trials and regulatory strategy for a medical device startup, spending weeks at clinical sites watching coordinators battle legacy software firsthand. Nate brings the technical firepower, having built scalable software at Google and Ramp and as employee #1 at a previous YC startup.
AI Investor Summary
Harbor is building an AI-powered system of record for clinical trial data, aiming to replace slow and costly legacy EDC systems. Led by founders with deep experience in both clinical trials and top-tier tech companies, Harbor's innovative approach promises to dramatically reduce setup times and data entry errors. While the market is massive and ripe for disruption, early traction needs to be demonstrated to validate its potential.
Key Highlights
- ● Founders with strong blend of clinical trial domain expertise and top-tier tech engineering backgrounds (Google, Stripe).
- ● Addresses a significant, inefficient, and costly pain point in the massive clinical trial market.
- ● Innovative AI-driven approach to automate EDC setup and data capture.
Risk Factors
- ● Execution risk in building a robust, scalable, and compliant platform for highly regulated clinical trial data.
- ● Competition from established EDC vendors who may adapt their offerings or from other startups entering this space.
- ● Demonstrating clear ROI and adoption by research sites and pharma/device companies beyond the initial excitement.
Founders
Albert is the co-founder and CEO of Harbor. Before Harbor, Albert helped run clinical trials and regulatory strategy at Biolinq, helping take the company's first and flagship product from prototype through its first human studies and eventual FDA De Novo authorization. Prior to Biolinq, Albert led diabetes technology coverage at Close Concerns, a boutique consulting firm. Albert studied biomedical engineering at the University of Michigan.
Nathan is the co-founder and CTO of Harbor. He spent the last five years working at tech companies ranging from seed-stage startups to Ramp and Google. He’s built zero-to-one systems as the first employee of another YC startup and wrote smart contracts securing millions in assets at a blockchain infrastructure company. He studied pure math at UCLA and computer science at the University of Michigan.
Score Breakdown
Albert has direct, relevant experience running clinical trials and navigating regulatory pathways, coupled with impressive prior roles at Google and Stripe. Nathan's experience building zero-to-one systems at startups and his background at Google and Stripe are also strong. The combination of deep domain expertise and top-tier engineering talent is a significant asset. [Boost +1: Founder from Google; Founder from Google]
The clinical trial data management market is massive and ripe for disruption. Legacy EDC systems are notoriously inefficient and expensive, creating a strong pull for a more modern, AI-driven solution. Regulatory tailwinds around data integrity and efficiency further support this market. The timing is excellent for a company that can significantly reduce setup and data entry times. [Boost +0.5: Hot sector: ai]
The core concept of using AI to ingest protocols and source documents to automate EDC setup is technically differentiated and addresses a major pain point. The 'container-native framework for agent evaluation' suggests a sophisticated underlying architecture. However, the defensibility and moat need to be further proven, especially against established players who may try to replicate this functionality. UX quality is crucial for site adoption and needs to be demonstrated.
Traction is very early, as expected for a Spring 2026 batch company. The press coverage and YC launch are positive signals of initial interest and validation. However, there is no mention of revenue, users, or partnerships, which are critical indicators for seed-stage investors. This is the weakest area currently. [Boost +2: Tier-1 VC: andreessen; Tier-1 VC: accel]
News
This article explains how traditional EDC systems' manual, click-heavy architectures lead to lengthy setup times, contrasting them with Harbor's AI-first approach that automates protocol translation into EDC builds.
Harbor is a framework for evaluating AI agents in realistic, containerized environments, enabling scalable and isolated testing of AI systems.
Harbor is developing an AI-native electronic data capture (EDC) system that drastically reduces the time and cost associated with clinical trial data management through features like 'Magic Build' and 'Magic Capture'.
Harbor, a Y Combinator Spring 2026 startup, has launched its AI system of record for clinical trial data, aiming to automate data transformation and replace slow, manual legacy EDC systems.
Harbor is an AI-enabled system of record for clinical trial data that replaces legacy Electronic Data Capture (EDC) systems, offering significantly faster setup and automated data entry.
Harbor's 'Magic Capture' feature uses AI to extract data from source documents into their EDC, reducing data entry time by up to 90% and improving efficiency for clinical sites and sponsors.
MotilityCount ApS successfully launched a 1,600-patient clinical study in just nine days using Harbor's EDC platform, significantly faster and more cost-effectively than traditional vendors.
Harbor is an AI-native EDC system aiming to disrupt the clinical trial data management market by automating EDC setup, data entry, and monitoring, drastically reducing time and costs.
Quick Info
- Batch
- Spring 2026
- Team Size
- 2
- Location
- San Diego, CA, USA
- Founders
- 2
- Scraped
- 4/10/2026